Gastrointestinal symptoms like nausea, vomiting, and also abdominal pain can result in emergency medical situations. It is quite challenging for clinicians to treat all those patients exhibiting these symptoms, especially when they do not show any signs of suffering from organic disease. In recent times, healthcare expenditures are already touching the sky. Thus, it would become challenging for individuals to make frequent trips to emergency rooms only for alleviating symptoms like vomiting and nausea. In 2011, a study was carried out by Chiba and also Kinoshita for discovering the therapeutic effects of famotidine on patients suffering from lasting symptomatic gastritis.
The management procedure followed for patients suffering from lasting symptomatic gastritis is different in several areas across the world. Take, for example, studies carried out on the same subject in Japan. However, it showed that the patients with upper abdominal signs were suffering from lasting symptomatic gastritis. But it was without endoscopic or histologic evidence. These patients were offered mucoprotective elements for relief.
Situations are entirely different in the western countries where patients with symptomatic gastritis showed signs of functional dysplasia. To precisely consider the diagnosis of FD, patients should show any one of the four essential symptoms. Those are postprandial epigastric fullness, epigastralgia, early satiation, and also epigastric burning.
Relevance Of The Study Of Effects Of Famotidine
Speaking of Japan, the category of lasting symptomatic gastritis includes a larger number of patients in comparison to functional dyspepsia. Therefore, patients showing non-typical signs like nausea might have lasting gastritis. The capability of famotidine is discovered in the field of treating severe symptomatic gastritis while being useful for functional dysplasia in the very first place.
The main objective of the study was to determine whether the patients of symptomatic gastritis made a response to the therapeutic effects of famotidine in the same way as the patients of functional dysplasia.
Highlights Of The Study
This study was carried out on 10, 311 patients suffering from symptomatic gastritis. Pathological, laboratory and also endoscopic examinations were not important for confirming the presence of symptomatic gastritis and the absence of abdominal diseases. Patients chosen for this study were the ones suffering from functional gastroduodenal problems like weak reflux symptoms. Among the 10, 311 patients selected for the study, 8, 640 of them responded appropriately.
The study protocol involved administering famotidine 20 mg to all the patients for four weeks. Moreover, the patients had to maintain a diary where they would jot down their abdominal signs. Face scales helped in assessing the intensity of symptoms like epigastric fullness, heartburn, and also epigastralgia. Even a questionnaire was in place before administering famotidine.
Results Of The Study
Of all the different patients diagnosed with symptomatic gastritis, around 5% or 155 of them were found suffering from organic diseases like gastric cancer and also peptic cancer. Approximately 68.0% of the patients showed signs of epigastralgia. Moreover, 48.2% showed heartburn, and 67.5% showed epigastric fullness. The study also put forward that the intensity of all these symptoms decreased in the patients as soon as they get 20 mg doses of famotidine.